Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Atara Biotherapeutics Inc

Healthcare US ATRA

11.275USD
0.67(6.27%)

Last update at 2026-06-23T15:04:00Z

Day Range

10.4311.35
LowHigh

52 Week Range

3.9219.14
LowHigh

Fundamentals

  • Previous Close 10.61
  • Market Cap40.81M
  • Volume33269
  • P/E Ratio1.94
  • Dividend Yield-%
  • EBITDA51.59M
  • Revenue TTM120.77M
  • Revenue Per Share TTM9.63
  • Gross Profit TTM 74.62M
  • Diluted EPS TTM2.57

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 32.72M -85.41500M -276.11100M -228.29000M -340.09500M
Minority interest - - - - -
Net income 32.69M -85.40300M -276.12600M -228.30200M -340.14100M
Selling general administrative 26.25M 39.89M 50.91M 71.55M 78.80M
Selling and marketing expenses - - 1.11M - -
Gross profit 99.56M 107.93M -0.31300M 49.01M 20.34M
Reconciled depreciation 2.12M 5.05M 4.88M 5.65M 9.35M
Ebit 49.77M -80.80000M -269.27600M -280.51300M -340.46200M
Ebitda 50.41M -75.74900M -264.44700M -330.75000M -331.11700M
Depreciation and amortization 0.64M 5.05M 4.83M -50.23700M 9.35M
Non operating income net other - - - 52.22M 0.37M
Operating income 35.86M -83.43800M -269.27600M -280.51300M -340.46200M
Other operating expenses 84.91M 212.38M 277.85M 344.09M 360.80M
Interest expense 3.79M 4.62M 5.29M 1.99M 9.71M
Tax provision 0.03M -0.01200M 0.00600M 0.01M 0.05M
Interest income 0.68M 2.11M 4.80M 1.99M 0.37M
Net interest income -3.10900M -2.50500M 0.94M 1.99M 0.37M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.03M -0.01200M 0.01M 0.01M 0.05M
Total revenue 120.77M 128.94M 8.57M 63.57M 20.34M
Total operating expenses 63.70M 191.37M 268.96M 344.09M 360.80M
Cost of revenue 21.21M 21.01M 8.89M 14.57M 11.38M
Total other income expense net -3.14300M -1.97700M -6.83500M 52.22M 0.37M
Discontinued operations - - - - -
Net income from continuing ops 32.69M -85.40300M -290.24800M -228.30200M -340.14100M
Net income applicable to common shares - - - -228.30200M -340.14100M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 20.23M 109.10M 165.50M 376.42M 468.13M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 2.48M 10.26M 6.18M 10.31M 12.57M
Total liab 58.74M 206.38M 264.74M 249.78M 188.51M
Total stockholder equity -38.50200M -97.28300M -99.23100M 126.64M 279.61M
Deferred long term liab - - - - -
Other current liab 3.30M 21.20M 48.53M 50.41M 44.91M
Common stock 0.00100M 0.00100M 0.01M 0.01000M 0.00900M
Capital stock 0.00100M 0.00100M 0.01M 0.01000M 0.00900M
Retained earnings -2021.86500M -2054.55300M -1969.15000M -1693.02400M -1464.72200M
Other liab - - - 109.16M 57.21M
Good will - - - - -
Other assets - - 0.00000M 7.02M 3.57M
Cash 8.48M 25.03M 25.99M 92.94M 106.08M
Cash and equivalents - - - - -
Total current liabilities 14.92M 134.57M 142.23M 78.92M 105.79M
Current deferred revenue 0.72M 95.09M 77.83M 8.00M 40.76M
Net debt 44.32M 18.80M 31.89M -21.23800M -80.56600M
Short term debt 10.78M 13.92M 12.18M 13.64M 2.75M
Short long term debt - - - - -
Short long term debt total 52.80M 43.83M 57.87M 71.70M 25.52M
Other stockholder equity 1983.36M 1957.26M 1870.11M 1821.72M 1744.69M
Property plant equipment - - - 6.30M 79.94M
Total current assets 12.21M 64.89M 101.87M 295.08M 384.62M
Long term investments - - - - -
Net tangible assets - - - 126.64M 279.61M
Short term investments 0.00000M 17.47M 25.88M 149.88M 264.98M
Net receivables 1.25M 1.48M 34.11M 40.22M 0.99M
Long term debt - - - - -
Inventory 0.00000M 10.65M 9.71M 1.59M -
Accounts payable 0.13M 4.37M 3.68M 6.87M 17.37M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.00100M 0.00800M -0.20400M -2.06700M -0.36800M
Additional paid in capital - - - - -
Common stock total equity - - - 0.01000M 0.00900M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -1693.02400M -1464.72200M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.89M 3.10M 4.84M 7.02M 3.57M
Deferred long term asset charges - - - - -
Non current assets total 8.02M 44.20M 63.63M 81.34M 83.51M
Capital lease obligations 10.38M 43.83M 57.87M 71.70M 25.52M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 17.20M 8.62M 165.14M 112.38M 32.84M
Change to liabilities - - - -25.74900M 44.28M
Total cashflows from investing activities 18.15M 8.62M - 202.96M 22.26M
Net borrowings -0.25000M -0.89200M - 30.09M -0.25400M
Total cash from financing activities 16.10M 59.28M 2.01M 53.08M 103.94M
Change to operating activities - - - 0.03M 8.04M
Net income 32.69M -85.40300M -276.12600M -228.30200M -340.14100M
Change in cash -16.69400M -0.81100M -67.10100M -14.39000M -94.32000M
Begin period cash flow 25.18M 25.99M 93.09M 107.48M 201.80M
End period cash flow 8.48M 25.18M 25.99M 93.09M 107.48M
Total cash from operating activities -50.94000M -68.71700M -192.97700M -270.43000M -220.52200M
Issuance of capital stock 16.31M 59.95M 32.57M 52.50M 98.70M
Depreciation 2.38M 5.05M 4.83M 5.65M 9.35M
Other cashflows from investing activities 0.95M - - 94.77M -
Dividends paid - - - 0.62M 1.24M
Change to inventory 10.65M -4.43400M -8.12000M -1.58600M 3.34M
Change to account receivables 0.23M 32.63M 6.11M -39.23500M 0.26M
Sale purchase of stock - - -0.09400M -0.62300M -1.24400M
Other cashflows from financing activities -0.00100M 0.22M -0.10700M 2.35M 7.99M
Change to netincome - - - 3.60M 57.60M
Capital expenditures 0.00000M 0.25M 1.22M 4.19M 10.58M
Change receivables - - - -39.23500M 0.26M
Cash flows other operating - - - 14.16M 4.18M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - -14.39000M -94.32000M
Change in working capital -104.73500M -30.95900M 15.34M -61.46800M 52.58M
Stock based compensation 9.75M 27.00M 45.39M 53.84M 53.87M
Other non cash items 8.98M 15.59M 12.46M -40.15100M 2.04M
Free cash flow -50.94000M -68.96300M -194.20000M -274.62300M -231.10200M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ATRA
Atara Biotherapeutics Inc		 0.67 6.27% 11.28 1.94 232.56 0.34 16.14 0.35 1.11
NVO
Novo Nordisk A/S		 1.15 2.51% 47.03 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.41 0.30% 468.20 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.50 1.06% 619.00 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Atara Biotherapeutics Inc

1280 Rancho Conejo Blvd, Thousand Oaks, CA, United States, 91320

Key Executives

Name Title Year Born
Dr. Pascal Touchon D.V.M. Pres, CEO & Director 1963
Mr. Utpal Koppikar M.B.A. Exec. VP & CFO 1971
Mr. K. Amar Murugan Sr. VP & Gen. Counsel 1975
Dr. Jakob Dupont M.D. Exec. VP and Global Head of R&D 1965
Ms. Charlene Banard Chief Technical Officer 1963
Dr. Anhco Nguyen Chief Scientific Officer 1973
Eric Hyllengren VP of Investor Relations & Fin. NA
Kerry Beth Daly Head of Corp. Communications NA
Ms. Amie Krause Chief People Officer NA
Mr. Joseph Newell Exec. VP 1970

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.